- Home
- SIGI vs TLX Comparison
SIGI vs TLX Comparison
Compare SIGI & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGI
- TLX
- Stock Information
- Founded
- SIGI 1926
- TLX 2015
- Country
- SIGI United States
- TLX Australia
- Employees
- SIGI N/A
- TLX N/A
- Industry
- SIGI Property-Casualty Insurers
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- SIGI Finance
- TLX Health Care
- Exchange
- SIGI Nasdaq
- TLX Nasdaq
- Market Cap
- SIGI 5.2B
- TLX 5.7B
- IPO Year
- SIGI N/A
- TLX N/A
- Fundamental
- Price
- SIGI $86.25
- TLX $16.12
- Analyst Decision
- SIGI Hold
- TLX Strong Buy
- Analyst Count
- SIGI 8
- TLX 2
- Target Price
- SIGI $94.00
- TLX $22.00
- AVG Volume (30 Days)
- SIGI 378.2K
- TLX 39.0K
- Earning Date
- SIGI 07-17-2025
- TLX 01-01-0001
- Dividend Yield
- SIGI 1.77%
- TLX N/A
- EPS Growth
- SIGI N/A
- TLX 798.14
- EPS
- SIGI 3.68
- TLX 0.09
- Revenue
- SIGI $4,981,891,000.00
- TLX $484,687,790.00
- Revenue This Year
- SIGI $6.05
- TLX N/A
- Revenue Next Year
- SIGI $7.43
- TLX N/A
- P/E Ratio
- SIGI $23.37
- TLX $175.37
- Revenue Growth
- SIGI 13.30
- TLX 55.85
- 52 Week Low
- SIGI $78.13
- TLX $13.61
- 52 Week High
- SIGI $103.56
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- SIGI 47.69
- TLX N/A
- Support Level
- SIGI $84.24
- TLX N/A
- Resistance Level
- SIGI $87.88
- TLX N/A
- Average True Range (ATR)
- SIGI 2.00
- TLX 0.00
- MACD
- SIGI 0.03
- TLX 0.00
- Stochastic Oscillator
- SIGI 39.43
- TLX 0.00
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.